tiprankstipranks
Trending News
More News >
Tyra Bioscience (TYRA)
NASDAQ:TYRA
US Market

Tyra Bioscience (TYRA) AI Stock Analysis

Compare
78 Followers

Top Page

TY

Tyra Bioscience

(NASDAQ:TYRA)

Rating:41Neutral
Price Target:
Tyra Bioscience's overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.
Positive Factors
Clinical Trial Progress
The first patient has been dosed in the Phase 2 trial of TYRA-300 for non-muscle invasive bladder cancer, marking a significant milestone in its clinical development.
Economic Incentive
Community urologists have an economic incentive to prescribe TYRA-300, as it may be available through a popular group purchasing organization, UroGPO.
Product Differentiation
TYRA-300's oral administration could make it a more appealing option for patients by reducing the need for regular hospital visits.
Negative Factors
Competitive Landscape
TYRA-300 faces significant competition in the market from existing pan-FGFR inhibitors, despite its selective targeting.

Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)

Tyra Bioscience Business Overview & Revenue Model

Company DescriptionTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
How the Company Makes MoneyTyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary
Tyra Bioscience's financials reflect its focus on research and development in the biotechnology sector. The company has zero revenue and increasing losses, typical for investing in future growth. Strong liquidity through cash reserves is offset by reliance on external financing and negative profit margins, indicating a high-risk profile.
Income Statement
10
Very Negative
Tyra Bioscience has consistently reported zero revenue, which is typical for early-stage biotechnology firms focusing on research and development. The company shows increasing losses over the years, with a notable rise in EBIT and net losses, indicating higher operational expenses. This results in negative profit margins, reflecting the company's developmental stage and need for capital investment.
Balance Sheet
40
Negative
The balance sheet shows strong liquidity with significant cash and short-term investments, outpacing total debt, resulting in negative net debt. The equity ratio is robust, showing a high proportion of assets financed by equity, which is positive for stability. However, the company's negative stockholders' equity in previous years reflects accumulated losses, posing a potential risk.
Cash Flow
30
Negative
Cash flow analysis reveals negative operating cash flow, typical for a company in the R&D phase. The high free cash flow outflow, though concerning, is offset by strong financing cash flow, suggesting reliance on external funding. The absence of revenue growth limits free cash flow growth, highlighting reliance on external capital to sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-353.00K-296.00K-140.00K-47.00K
EBITDA-104.18M-79.59M-58.63M-26.15M-9.25M
Net Income-86.48M-69.13M-51.72M-26.14M-9.31M
Balance Sheet
Total Assets363.56M225.86M266.18M306.70M16.01M
Cash, Cash Equivalents and Short-Term Investments341.44M203.47M251.21M302.18M15.22M
Total Debt6.22M6.50M2.62M1.18M142.00K
Total Liabilities20.41M21.59M8.35M4.96M29.65M
Stockholders Equity343.15M204.26M-95.70M301.74M-13.64M
Cash Flow
Free Cash Flow-70.44M-50.91M-50.84M-24.41M-8.07M
Operating Cash Flow-69.77M-50.14M-50.28M-23.75M-7.76M
Investing Cash Flow-98.40M-144.60M-559.00K-645.00K-312.00K
Financing Cash Flow202.14M1.54M632.00311.35M23.43M

Tyra Bioscience Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.05
Price Trends
50DMA
9.88
Positive
100DMA
10.19
Negative
200DMA
14.11
Negative
Market Momentum
MACD
-0.04
Positive
RSI
53.44
Neutral
STOCH
61.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 10.05 is above the 20-day moving average (MA) of 9.94, above the 50-day MA of 9.88, and below the 200-day MA of 14.11, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 53.44 is Neutral, neither overbought nor oversold. The STOCH value of 61.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.

Tyra Bioscience Risk Analysis

Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tyra Bioscience Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$520.77M-216.14%203.23%-80.71%
57
Neutral
$545.51M-31.46%6.11%-37.79%
55
Neutral
$568.61M-63.53%-47.94%30.94%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
46
Neutral
$541.81M0.71%91657.69%97.21%
41
Neutral
$516.89M-27.04%6.72%
40
Neutral
$504.70M-37.07%26.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TYRA
Tyra Bioscience
10.05
-7.05
-41.23%
TBPH
Theravance Biopharma
11.05
2.29
26.14%
SAGE
SAGE Therapeutics
9.08
-1.70
-15.77%
MNMD
Mind Medicine
7.08
0.00
0.00%
MGTX
Meiragtx Holdings
6.92
2.90
72.14%
KROS
Keros Therapeutics
13.41
-28.80
-68.23%

Tyra Bioscience Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Tyra Biosciences Appoints Adele M. Gulfo to Board
Positive
Jan 29, 2025

Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025